Market news

The heavy selling pressure might have exhausted for Caribou Biosciences (CRBU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Caribou Biosciences (CRBU) has an average rating of buy and mean price target of $11.86, according t

Caribou Biosciences (CRBU) delivered earnings and revenue surprises of +27.27% and -40.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

-- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies and that vispa-cel has the potential to overcome access barriers for patients with 2L LBCL -- -- CaMMouflage dose escalation phase 1 data presented at EHA 2026 demonstrate single dose of CB-011 produced deep, durable responses in high-risk, late-line BCMA-naïve r/r MM patients; initial dose expansion data in BCMA-naïve and BCMA-exposed patient

Here is how Caribou Biosciences, Inc. (CRBU) and Bioventus (BVS) have performed compared to their sector so far this year.

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Multiple Myeloma pipeline constitutes 75+ key companies continuously working towards developing 80+ Multiple Myeloma treatment therapies, analysis of Clinical Trials, Ther...